First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Open Access
- 29 October 2008
- journal article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 1 (1), 20
- https://doi.org/10.1186/1756-8722-1-20
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete RemissionClinical Cancer Research, 2012
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinJournal of Clinical Oncology, 2008
- Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Telomere dysfunction and tumour suppression: the senescence connectionNature Reviews Cancer, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Thrombospondins: from structure to therapeuticsCellular and Molecular Life Sciences, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2007
- The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivoMolecular Cancer Therapeutics, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Focal adhesion kinase as a potential target in oncologyExpert Opinion on Pharmacotherapy, 2003